Cancer Family
Testicular Germ Cell Tumor
CI-CAN-00000362TGCTExplore in graph →
Non-malignant13 active trials
- NCIt
- C8591
- Other
- 1 more code
Loading cancer entity…
Cancer Family
CI-CAN-00000362TGCTExplore in graph →
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07614620 | Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer(HYPNO-AJA2) | recruiting | N/A | 70 | Institut BergoniéOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07777887 | Sentinel Node Identification Using Gamma and Near-Infrared Imaging in TesticulAr MaLignancies(SIGNAL) | recruiting | — | 60 | N.N. Petrov National Medical Research Center of Oncology |
| 1 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT06060873 | MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial | recruiting | — | 418 | University of Southern CaliforniaOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07218913 | Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors | recruiting | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07463508 | Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity(TG-BIL) | recruiting | N/A | 20 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07453082 | A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors(BRIDGE) | recruiting | — | 100 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05345158 | R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma | recruiting | N/A | 25 | University Health Network, TorontoOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05670938 | Follow-up After Surgery for Testicular Cancer(FUTURE-testis) | recruiting | — | 145 | Erasmus Medical CenterOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04914026 | MicroRNA as Markers in Testicular Cancer | recruiting | — | 350 | Haukeland University HospitalOTHER | 2 | Aug 8, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials